Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
QL1706 + fruquintinib
- Development stage
- Unknown
- Lead developer
- Qilu Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
QL1706 + fruquintinib is an investigational combination therapy consisting of epalolitovoreli (QL1706), a bispecific monoclonal antibody, and fruquintinib, a highly selective small-molecule tyrosine kinase inhibitor. Epalolitovoreli is designed to simultaneously target and block the PD-1 and CTLA-4 immune checkpoints, potentially providing a more robust anti-tumor immune response than single-agent checkpoint inhibitors. Fruquintinib selectively inhibits VEGFR-1, -2, and -3, thereby suppressing tumor angiogenesis and potentially modulating the tumor microenvironment to be more receptive to immunotherapy. This combination is being actively studied in patients with metastatic colorectal cancer, particularly those with microsatellite stable (MSS) or proficient mismatch repair (pMMR) status, often in conjunction with radiotherapy to enhance therapeutic efficacy in liver-metastatic disease.
- Brand names
- Elunate
- Other names
- Epalolitovoreli + fruquintinibQL1706 plus fruquintinibQL-1706 plus fruquintinibQL 1706 plus fruquintinib
02
Targets
VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FGFR1 (Fibroblast growth factor receptor 1)
Beyond the preview
Go deeper on QL1706 + fruquintinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on QL1706 + fruquintinib.